Q2 Earnings Forecast for CAPR Issued By B. Riley

Key Points

• B. Riley has set a **Q2 2026 EPS estimate** for Capricor Therapeutics at **($0.42)**, maintaining a **"Strong-Buy" rating** on the stock.
• Capricor Therapeutics reported **($0.57) EPS** for its last quarter, missing expectations by **($0.09)**, and has a **negative return on equity** of **62.71%**.
• The stock has seen **institutional interest** with Tower Research increasing its stake by **280.8%**, while **21.68%** of shares are currently held by institutional investors and hedge funds.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Analysts at B. Riley issued their Q2 2026 earnings per share estimates for shares of Capricor Therapeutics in a note issued to investors on Sunday, September 14th. B. Riley analyst M. El-Saadi forecasts that the biotechnology company will post earnings of ($0.42) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. B. Riley also issued estimates for Capricor Therapeutics' Q3 2026 earnings at ($0.39) EPS and Q4 2026 earnings at $2.34 EPS.

Other analysts also recently issued research reports about the company. Piper Sandler reiterated an "overweight" rating and set a $20.00 price target on shares of Capricor Therapeutics in a research report on Friday, July 11th. Jones Trading dropped their price target on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, June 25th. Oppenheimer dropped their target price on Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a research report on Monday, June 23rd. Roth Capital dropped their target price on Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating for the company in a research report on Monday, July 14th. Finally, HC Wainwright reissued a "buy" rating and set a $24.00 target price on shares of Capricor Therapeutics in a research note on Thursday, September 11th. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $22.56.

Capricor Therapeutics Trading Up 3.9%

Shares of CAPR traded up $0.25 during trading hours on Tuesday, reaching $6.65. 1,851,794 shares of the company's stock traded hands, compared to its average volume of 1,069,122. The stock has a market cap of $304.04 million, a PE ratio of -4.05 and a beta of 0.73. The firm's 50 day simple moving average is $7.01 and its 200-day simple moving average is $9.57. Capricor Therapeutics has a 12 month low of $4.93 and a 12 month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its position in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company's stock worth $67,000 after buying an additional 4,976 shares in the last quarter. Citizens Financial Group Inc. RI purchased a new stake in Capricor Therapeutics in the first quarter worth about $95,000. KLP Kapitalforvaltning AS increased its position in Capricor Therapeutics by 65.2% in the second quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company's stock worth $108,000 after buying an additional 4,300 shares in the last quarter. Arizona State Retirement System purchased a new stake in Capricor Therapeutics in the first quarter worth about $111,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Capricor Therapeutics by 31.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company's stock worth $126,000 after buying an additional 3,162 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.